Medicinal Chemistry News and Research

RSS

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Advanced Life Sciences Holdings, Inc.,a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents.

31 Aug 2010

AgeneBio receives grant to develop neural stabilizer therapy for amnestic mild cognitive impairment

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.

27 Aug 2010

Bioniche, University of Ottawa sign global technology license agreement for botanical therapeutics

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada's top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa's technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture

25 Aug 2010

Ensemble Therapeutics showcases data on new drug discovery platform at ACS National Meeting

Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

24 Aug 2010

Numerate collaborates with Intellikine to identify drug-like inhibitors of PI3 kinase alpha

Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine's unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate's powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.

12 Aug 2010

Elsevier Properties congratulates Stewart for achieving Lectureship

Elsevier Properties SA is pleased to congratulate Dr. Scott Stewart on his winning the Royal Australian Chemical Institute's (RACI) 2010/11 Athel Beckwith Lectureship, sponsored by Reaxys.

6 Aug 2010

AMRI second-quarter adjusted EPS increases to $0.06

AMRI today reported financial and operating results for the second quarter ended June 30, 2010.

5 Aug 2010

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

A new biotech company has grown out of laboratory and clinical studies at the Medical College of Georgia with the goal of improving the diagnosis and treatment of diabetes and cancer.

20 Jul 2010

Rottapharm Madaus, Selvita sign drug discovery services contract

Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.

20 Jul 2010

Biotage introduces ExploraSep 96-well screening plates to identify optimum scavengers

Biotage, a leading supplier of tools and technology for analytical and medicinal chemistry, announced the introduction of ExploraSep 96-well screening plates to identify optimum scavengers. The 4 different screening plates deliver 128 selective resins based on high-performance, Molecularly Imprinted Polymers (MIPs). Biotage provides professional MIPs technical consultation, information on additional formats as well as assistance with data interpretation and process development.

15 Jul 2010

MRC Technology, Genentech sign licensing agreement

MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease.

12 Jul 2010

Calithera Biosciences completes Series A financing totaling $40M

Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.

8 Jul 2010

TB Alliance, DNDi announce inter-PDP agreement to develop potential anti-TB compounds

The Global Alliance for TB Drug Development and Drugs for Neglected Diseases initiative announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world's poor.

8 Jul 2010

Biotage launches AFFINILUTE Molecularly Imprinted Polymer columns for analytical sample preparation

Biotage, a leading supplier of tools and technology for analytical and medicinal chemistry, announced the introduction of high-performance, AFFINILUTE MIP (Molecularly Imprinted Polymers) columns for analytical sample preparation. Highly selective extractions with AFFINILUTE MIPs are considerably simplified resulting in faster, more robust and ultimately lower cost sample preparation.

7 Jul 2010

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

The Florida Biomedical Research Program has awarded $2 million in biomedical research grants to three scientists from the Florida campus of The Scripps Research Institute.

1 Jul 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

Overview of scientific research on medical technology to combat anthrax threat

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

25 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

Pfizer to join SGC-led collaboration to generate chemical probes for proteins involved in epigenetic signalling

The Structural Genomics Consortium (SGC) and Pfizer today announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors - "chemical probes" - for proteins involved in epigenetic signalling.

11 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010